Compares quality of life and outcomes of newer and standard immunotherapies in relapsed myeloma
Observes quality of life and treatment results in adults with relapsed or refractory multiple myeloma.
Key facts
- Who runs it
- Sung-Soo Park
- Where
- Seocho, South KoreaSee the site
- Trial code
- Registry title
- Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
- Status
- Recruiting
- People taking part
- 174 people, planned
- Started
- 14 Jul 2025
- Planned end
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Bispecific antibody
- Antibody-Drug Conjugate
- Monoclonal antibody
- Proteasome Inhibitor
- IMiD treatment
- CAR-T Therapy
- Record updated
- 15 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. They must have had three types of earlier drugs and be about to start a new immunotherapy.
- Age
- 19 years or older
- Sex
- Women and men
- Disease stage
- Multiple myeloma that came back (relapsed) or did not respond (refractory), diagnosed between the IRB approval date and December 2025
- Earlier treatment
- Must have had at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody. Must be scheduled to start advanced or conventional immuno-oncology treatment within one month from screening.
Main reasons for not taking part
- Does not agree to take part
- Another plasma cell disorder instead of multiple myeloma (for example lymphoma or POEMS syndrome)
- Cannot read and understand documents written in Korean
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Male or female aged 19 years or older
- Diagnosed with multiple myeloma and have been previously treated with at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody treatment (i.e., exposed to all three classes of immunotherapy agents)
- Diagnosed with relapsed or refractory multiple myeloma between the IRB approval date and December 2025, and scheduled to start treatment with either advanced immuno-oncology agents or conventional immuno-oncology agents within one month from screening
- Provided written informed consent after receiving detailed explanation about the study and voluntarily agreed to participate and comply with study requirements
Who cannot take part
- Patients diagnosed with plasma cell disorders other than multiple myeloma (e.g., lymphoma, POEMS syndrome)
- Those who do not agree to participate in the study
- Individuals unable to read and understand documents written in Korean
Where in South Korea
- Seoul St. Mary HospitalSeocho, South KoreaContact: Sung-Soo Park, MD.PhDTaking people
About the trial
What the trial wants to find out
This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or refractory multiple myeloma. A total of 174 participants are expected to be enrolled in this study.
Read full original descriptionShow less
The study consists of three parts:
Part 1 is the screening and enrollment phase, during which inclusion and exclusion criteria will be assessed for individuals who have agreed to participate in the study. Eligible participants will be enrolled, and data will be collected on their prioritized treatment value criteria.
Part 2 is the treatment phase, during which participants will receive either conventional immuno-oncology therapy or advanced immuno-oncology agents. Participants will visit the site on Day 1 of each treatment cycle to complete patient-reported outcomes (PROs), and efficacy and safety assessments will be conducted.
Part 3 is the end-of-study visit, during which PROs will again be collected, along with final efficacy and safety assessments.
Additionally, for exploratory purposes, bone marrow and peripheral blood samples will be collected from participants at Seoul St. Mary's Hospital who have consented to sample collection and provision during the study period.
The 2 groups in the trial
- Advanced Immuno-oncology Therapy Group
Treatment: Bispecific antibody and CAR-T Therapy
- Conventional Immuno-oncology Therapy Group
Treatment: Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor, and IMiD treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Observational Study of Quality of Life, Efficacy, and Safety Following Administration of Advanced Immuno-Oncology Agents Versus Conventional Immunotherapies in Patients With Relapsed/Refractory Multiple Myeloma
- Plain-language title
- Compares quality of life and outcomes of newer and standard immunotherapies in relapsed myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 July 2025